Mouwasat Medical Services Will Achieve a 25% Profit Margin in Just 3 Years

Overview

• P/E: 15.67
• RSI: 42 (Reflects the stock approaching relatively oversold areas due to the recent decline).
• Dividend Yield: 3.28%
• What is their moat: The company's economic moat consists of two main barriers: the massive capital cost of infrastructure (hospitals costing hundreds of millions) which prevents new competitors from easily entering the market, and the "network advantage" with its deep integration with major insurance companies, alongside regulatory complexities and Ministry of Health licensing. This moat ensures competitive pricing for services and profit margins that are among the highest in the Saudi healthcare sector.

Income & Revenue

• Current Revenue: SAR 3.29 billion (Trailing 12 Months).
• Annual Revenue Growth: 12.7% driven by increased bed occupancy rates.
• Gross Profit Margin: Approaching 45%.
• Operating Profit Margin: 29% (indicates efficient control over administrative expenses).
• Net Profit Margin: 25.5% (Net income exceeded SAR 822 million).
• General Trend: Stable upward growth coinciding with operational plans for new projects and an increased share of high-margin specialized surgeries.

Cash Flows

• Operating Cash Flow: Positive and growing, reflecting efficient management of the collection cycle from insurance companies.
• Free Cash Flow (FCF): Free cash flow remains positive despite being naturally impacted currently by massive expansionary capital expenditures.
• Cash Flow Growth: Growing at a rate almost parallel to revenue growth, proving that profits are converting into actual cash and not just book figures.
• Earnings Quality: Excellent; operating cash flows efficiently cover the realized net income.

Expenses & Costs

• Operating Costs: Concentrated in recruiting consultant doctors, salaries, and the depreciation of advanced medical equipment.
• Capital Expenditure (CapEx / Revenue): The ratio reaches levels around 15% to 20%. For companies in this heavy-asset sector, this vital ratio determines future competitiveness; continuous spending protects the quality of medical assets and ensures treatment technologies do not become obsolete.
• Research & Development: Low or almost non-existent, which is normal for healthcare providers relying on externally developed technologies.
• Management Efficiency:
  • Days Inventory Outstanding (DIO): The average holding period for medical and pharmaceutical inventory is 40 to 50 days. These levels financially protect the company from any waste or drug obsolescence and keep it far away from the risks of a cyclical margin downturn.
  • Return on Invested Capital (ROIC): Records approximately 18%, clearly exceeding the Weighted Average Cost of Capital (WACC) of about 8.5%. The positive spread confirms that management is not building hospitals just to expand, but is creating real economic value for every Riyal invested.

Market Share

• Current Market Share: Considered one of the top 4 private hospital operators in Saudi Arabia.
• Growth Trend: Horizontal expansion focusing on bridging geographical gaps (expanding in the capital and the southern region).
• Comparison with Competitors: Outperforms peers in net profit margins, although it ranks behind some competitors (like Al Habib) in total market capitalization.

Capital Growth

• Shareholders' Equity: Continuously expanding thanks to the profit reinvestment policy. The current book value stands at SAR 17.76 per share.
• Return on Equity (ROE): Stands at 23.2%, an exceptional efficiency indicator reflecting the maximization of owner returns.
• Asset Growth: An upward annual growth trend resulting from capital projects under construction (new hospitals and clinics).

Retained Earnings

• Retained Earnings Value: Represents the largest share of equity and is considered the primary funder of asset growth.
• Ratio to Capital: High, ensuring self-financing of expansions without excessive borrowing.
• Payout Ratio: A disciplined payout policy targeting the distribution of around 45% to 50% of net profits.

Dividends

• Dividend Yield: 3.28% at current prices.
• Annual Dividend: Stable distributions that have proven their worth at rates ranging between SAR 2.00 to 2.50 per share annually.
• Dividend Growth Rate: The company adopts an upward trajectory in dividends, maintained for over 9 consecutive years.
• Dividend History: Distributions are made semi-annually or quarterly (last entitlement in May 2026).

Sustainability & Financial Resilience

• Debt Ratio: Total debt to equity is balanced and completely controlled.
• Interest Coverage: Excellent; Earnings Before Interest and Taxes (EBIT) cover financing costs multiple times over.
• Credit Rating: The strong financial position grants it a borrowing capacity with competitive costs from local banks.
• Resilience Score: Defensive and recession-proof; the demand for healthcare is inelastic and unaffected by severe economic cycles.

Competitors & Competitive Intensity

• Competitive Intensity: High in the capital, Riyadh, due to the density of major players, but decreases dramatically in sub-regions dominated by the company, such as the Eastern Province.
• Competitive Advantages: Vertical integration of services and a standard hospital operating model that allows copying a successful branch's operations to a new one with minimal cost and administrative waste.

New Projects & Investments

• New Markets: Penetrating the Riyadh market with a massive project and expanding influence in Abha and the Southern Region.
• Investment Size: The Riyadh hospital at SAR 900 million and the Abha hospital at SAR 700 million. These projects are considered the primary drivers of revenue growth for the next three years.

Growth Opportunities & Risks

• Estimated Growth Rate: Revenues and profits are expected to grow at an average annual rate of 10% to 15% after the commercial operation of the new hospitals.
• Growth Catalysts: Positive demographic shifts and the mandatory increase in insurance coverage for citizens and residents.
• Risks: Scarcity of consultant medical competencies leading to higher wage costs, and the possibility of changes in insurance legislation pressuring profit margins.

Technical Indicators

• RSI: 42 (Confirms the absence of overbought conditions and that the stock is technically trading in a quiet zone leaning towards short-term negativity).
• MA 7: Price is below the fast intraday moving average.
• MA 30: Price is below the one-month average due to the recent gradual decline.
• MA 90: Shows a crossover leaning towards negativity.
• MA 200: Price level is very close to this strategic average.
• 52-Week High: SAR 80.70.
• 52-Week Low: SAR 58.65.
• Current Status: Initial rebound and consolidation near the annual lows.
• Technical Analysis Signal: Complete absence of impulsive buying momentum, indicating a suitable accumulation zone for an investor seeking a margin of safety away from peak volatility.

Valuation — Is the Stock Cheap or Expensive?

• P/E Ratio: 15.67x. This multiple is considered extremely low compared to the Saudi healthcare sector average, which trades at 21x and above, and does not reflect the company's strong current earnings growth rate.
• P/B Ratio: 3.55 (Trading at a high book multiple is financially justified due to ROE reaching 23%).
• EV/EBITDA: Trades around moderate multiples compared to the capital-intensive hospital industry.
• Estimated Fair Value: Analyst consensus points to a range of SAR 87.00 - 89.00.
• Upside/Downside Potential: A potential upside margin exceeding +34% to reach its reference fair value.
• Is the Stock Worth Buying Now? Fundamentally: Yes. The company is achieving record profits while the stock is trading at suppressed and discounted multiples relative to the sector.

Best Purchase Plan & Timing

• Entry Strategy: Gradual accumulation; seizing the opportunity without rushing by buying in tranches, taking advantage of calm technical indicators and the stock not being in overbought zones.
• Support Levels: SAR 64.50 then SAR 62.00.
• Price Targets: SAR 75.00 (initial), then SAR 87.00 (investment target).
• Stop Loss: Breaking the SAR 58.00 level and closing the week below it, which means a complete breakdown of the annual low and a structural trend change.
• Time Horizon: Medium to long-term investment (1 to 3 years).

Final Buy / Sell Signals

• Overall Signal: Investment Buy.
• Fundamentals Signal: Very Strong Buy (free cash flow, excellent P/E multiple, and an impenetrable financial moat).
• Technical Signal: Accumulation and positioning (entry with a margin of safety away from extreme peaks).

Exceptional Sales & Revenues

Financial records show the company is free of one-off exceptional revenues (like selling real estate assets to artificially inflate profits). The 12.7% sales growth stems entirely from direct operational activities (consultations, surgeries, and drug dispensing), confirming the pure quality and sustainability of earnings.

Intellectual Capital & Intangible Assets

In the healthcare sector, concrete assets alone are not enough to explain the true value:

• Value Added Intellectual Coefficient (VAIC™): The company's valuation scores excellent rates in this criterion. Management effectively succeeds in converting human capital (the skills of surgeons and specialists) into superior operating margins. Efficiency is clearly evident in the sustainable and reliable relational capital with major insurance companies.
• Cognitive Leverage: The company's success in automating patient files and implementing enterprise resource planning systems enhances the central system's ability to handle hundreds of thousands of medical visits flexibly. Every additional health data point analyzed reduces the rate of medical errors and accelerates bed turnover, thereby expanding production capacity without the need to add new physical spaces.

Integrating ESG Criteria as "Signaling"

• Social License to Operate: The company's compliance with medical waste disposal regulations and strict medical governance not only reflects social responsibility but acts as a structural shield protecting it from regulatory fines and ensuring the smooth renewal of operating licenses.
• The Inverted U-Relationship: The company's investment in sustainability sits at the optimal point for profitability. It invests in energy efficiency systems for new hospitals to reduce operating bills, but it does not surpass this point towards excessive cosmetic spending that could turn into a financial burden crushing margins.

Adopting "Real Options Analysis" instead of Static DCF

• Expanded Net Present Value (eNPV): Using dynamic valuation criteria, we see that the infrastructure of the new hospitals in Riyadh and Abha was designed with the "Option to Expand". The company can add clinics and beds later without a full operational shutdown. This real option adds financial value exceeding the traditional NPV by more than 15%.
• Value of Volatility: According to real options engineering, sudden volatility in seasonal health demand is a factor that increases the company's value, not decreases it. The company possesses the option of flexible pricing and redistributing intensive care capacities and elective surgeries to convert this volatility into blockbuster potential profits and absorb shocks.

Specialized Sectoral Valuation: Fair Price Assuming a 3-Year Horizon

• Residual Income: In precise sectoral models, a company that does not generate a return exceeding its cost of capital destroys shareholder wealth even if it achieves nominal profits. In the case of this company, with an estimated average cost of equity of 8.5% and a Return on Equity (ROE) of 23%, the company produces superior and positive "residual income" that pours directly into the book pool and increases the intrinsic value of the share annually.
• Adopted Strategy for Calculation (3-Year Residual Income Model):The value was calculated using the cumulative residual income formula:$V_0 = B_0 + \sum_{t=1}^{3} \frac{RI_t}{(1+r)^t} + \frac{P_3 - B_3}{(1+r)^3}$
  • Initial Book Value ($B_0$): SAR 17.76.
  • Positive Spread: Exceeds 14% between return and capital cost.
  • Growth Drivers (2026 - 2028): Operating massive projects worth SAR 1.6 billion will gradually raise capacity. Assuming EPS growth to reach around SAR 5.80 by the end of the period.
  • Target Value: Based on the dynamics of management's ability to generate residual income at a balanced growth multiple (17x at a slight discount from the historical average), the intrinsic fair price for the stock after 3 years is concentrated at SAR 98.60.
  The logic adopted here refuses to settle for discounted cash flows that are affected by phased capital expenditure, but rather measures management's professional ability to extract pure operating returns that structurally exceed the cost of invested funds.